Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b

doi:10.3748/wjg.v23.i46.8120

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9132)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

460

WORD

267

HTML

4709

Figures (1-1)

247

Tables (1-3)

204

Sum=5887

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

628

Download

626

Sum=1254

Publishing Process of This Article

Item

Count

Browse

961

Download

1030

Sum=1991

Dec 14, 2017 (publication date) through Sep 1, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Dec 14, 2017; 23(46): 8120-8127
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120

Table 3 Retreatment regimens for patients with hepatitis C virus infection for whom the initial combination of direct-acting antivirals has failed

Patients	APASL (2016)[1]	AASLD (2017)[28]
GT1
Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure non-cirrhotic patients	Sofosbuvir/ledipasvir 12 wk	Sofosbuvir/ledipasvir 12 wk
		Sofosbuvir/velpatasvir 12 wk
		Glecaprevir/pibrentasvir 12 wk
Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure compensated cirrhotic patients	Sofosbuvir/ledipasvir 12 wk	Sofosbuvir/velpatasvir 12 wk
		Glecaprevir/pibrentasvir 12 wk
		(For GT1b) Elbasvir/grazoprevir 12 wk
HCV NS5A inhibitors-failure non-cirrhotic patients	Wait	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
HCV NS5A inhibitors-failure compensated cirrhotic patients	RAS check	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
Non-NS5A inhibitor/ sofosbuvir-failure non-cirrhotic patients	N/A	Glecaprevir/pibrentasvir 12 wk
		(For GT1a)
		Sofosbuvir/velpatasvir/voxilaprevir 12 wk
		(For GT1b) Sofosbuvir/velpatasvir 12 wk
Non-NS5A inhibitor/ sofosbuvir-failure compensated cirrhotic patients	N/A	Glecaprevir/pibrentasvir 12 wk
		(For GT1a)
		Sofosbuvir/velpatasvir/voxilaprevir 12 wk
		(For GT1b) Sofosbuvir/velpatasvir 12 wk
GT2
Sofosbuvir/ribavirin-failure patients	N/A	Sofosbuvir/velpatasvir 12 wk
	N/A	Glecaprevir/pibrentasvir 12 wk
GT3
DAA (including NS5A inhibitors) - failure patients	N/A	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
	N/A	(For NS5A inhibitor-failure) weight-based ribavirin is recommended
GT4
DAA (including NS5A inhibitors) - failure patients	N/A	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
	N/A	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
GT5/GT6
DAA (including NS5A inhibitors) - failure patients	N/A	Sofosbuvir/velpatasvir/voxilaprevir 12 wk
	N/A	Sofosbuvir/velpatasvir/voxilaprevir 12 wk

DAAs: Direct-acting antivirals; HCV GTs: Hepatitis C virus genotypes; RAS: Resistance-associated variants; N/A: Not available.

Citation: Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127
URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8120.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8120